What's breaking now, across thousands of outlets.
Thomas Kahlert has been off HIV treatment since 2018 after a stem-cell transplant from a donor who was not HIV-resistant. Why it matters, and why it isn’t a cure for most people with HIV.
We haven't written up this one. 3News has the full story — the link below goes straight to it.
Imagine a teenager in a vulnerable mental health crisis being admitted to a ward full of adults. Thankfully, regional officials […]
Nashik: The Food and Drug Administration (FDA) has launched a crackdown on food safety violations in Nashik, seizing 151 kg of allegedly substandard cakes and cupcakes from Ajmeri Bakery in the…
Medical devices are emerging as the new kid on the block in India’s healthcare investment landscape, attracting private equity (PE) interest on the back of a fragmented market, rising demand and the…
The Series A round, which was led by RA Capital, will help fund the development of two genetic medicines designed to treat an inherited kidney disorder known as "ADPKD."
Estuary Biotherapeutics raised the curtain on Friday with $103 million to support the advancement of two preclinical gene therapy candidates for the most common type of inherited kidney disease.
